HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Abstract
FOXP3-expressing T regulatory lymphocytes (Tregs) have been described as putative mediators of immune tolerance, and thus facilitators of tumor growth. When found in association with various malignancies, Tregs are generally markers of poor clinical outcome. However, it is unknown whether they are also associated with cancer progression. We evaluated quantitative FOXP3 expression in lymphocytes as well as in epithelial cells in a set of thirty-two breast tumors with synchronous normal epithelium, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) components. Tumors were stained for FOXP3 and CD3 expression and Tregs quantified by determining the ratio of colocalized FOXP3 and CD3 relative to 1) total CD3-expressing lymphocytes and 2) to FOXP3-expressing epithelial cells. The median proportion of FOXP3-expressing CD3 cells significantly increased with malignant progression from normal to DCIS to IDC components (0.005, 0.019 and 0.030, respectively; p ≤ 0.0001 for normal vs. IDC and p = 0.004 for DCIS vs. IDC). The median intensity of epithelial FOXP3 expression was also increased with invasive progression and most markedly augmented between normal and DCIS components (0.130 vs. 0.175, p ≤ 0.0001). Both Treg infiltration and epithelial FOXP3 expression were higher in grade 3 vs. grade 1 tumors (p = 0.014 for Tregs, p = 0.038 for epithelial FOXP3), but did not vary significantly with hormone receptor status, size of invasive tumor, lymph node status, or disease stage. Notably, Treg infiltration significantly correlated with epithelial up-regulation of FOXP3 expression (p = 0.013 for normal, p = 0.001 for IDC). These findings implicate both Treg infiltration and up-regulated epithelial FOXP3 expression in breast cancer progression.
AuthorsAseem Lal, Loretta Chan, Sandy Devries, Koei Chin, Gary K Scott, Christopher C Benz, Yunn-Yi Chen, Frederic M Waldman, E Shelley Hwang
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 139 Issue 2 Pg. 381-90 (Jun 2013) ISSN: 1573-7217 [Electronic] Netherlands
PMID23712790 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Biomarkers, Tumor
  • CD68 antigen, human
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • p21-Activated Kinases
Topics
  • Adult
  • Aged
  • Antigens, CD (metabolism)
  • Antigens, Differentiation, Myelomonocytic (metabolism)
  • Biomarkers, Tumor (metabolism)
  • Breast Neoplasms (immunology, metabolism, pathology)
  • Carcinoma, Intraductal, Noninfiltrating (immunology, metabolism, pathology)
  • Disease Progression
  • Epithelium (metabolism)
  • Female
  • Forkhead Transcription Factors (metabolism)
  • Humans
  • Immunohistochemistry
  • Lymphocytes, Tumor-Infiltrating (immunology, metabolism)
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Stromal Cells (metabolism)
  • T-Lymphocytes, Regulatory (immunology, metabolism)
  • p21-Activated Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: